Compare ICCM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | FEMY |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 51.5M |
| IPO Year | N/A | 2021 |
| Metric | ICCM | FEMY |
|---|---|---|
| Price | $0.68 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $6.83 |
| AVG Volume (30 Days) | 403.0K | ★ 3.8M |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,975,000.00 | $2,061,502.00 |
| Revenue This Year | $13.67 | $64.02 |
| Revenue Next Year | $38.55 | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $0.59 | $0.31 |
| 52 Week High | $1.66 | $1.80 |
| Indicator | ICCM | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 47.72 |
| Support Level | $0.67 | $0.83 |
| Resistance Level | $0.73 | $0.96 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 56.00 | 32.25 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.